Drugs / Rocakinogene Sifuplasmid
Rocakinogene Sifuplasmid
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04367675 | Apr 2021 → Dec 2026 expected | hereditary neoplastic syndrome | Abramson Cancer Center at Penn Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04015700 | Jul 2020 → May 2022 overdue | glioblastoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02772003 | Jun 2016 → Mar 2020 overdue | hepatitis C virus infection, hepatocellular carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02514213 | Jul 2015 → Dec 2017 | prostate cancer | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02464670 | May 2015 → May 2018 | Ebola hemorrhagic fever | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02960594 | Dec 2014 → Nov 2018 | breast cancer, colorectal cancer, esophageal cancer, gastric cancer +5 | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02241369 | May 2014 → Sep 2018 | preneoplastic lesion | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04251117 | Mar 2020 → Nov 2024 overdue | hepatocellular carcinoma | Geneos Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03502785 | Jul 2018 → May 2025 | urothelial carcinoma | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03491683 | May 2018 → Dec 2026 expected | glioblastoma | Inovio Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02163057 | Aug 2014 → Jan 2017 | head and neck squamous cell carcinoma | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07722741 | Sep 2026 → Sep 2029 expected | hepatocellular carcinoma | Geneos Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT02501278 | May 2016 → May 2019 | cervical cancer | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03606213 Comparator | Aug 2018 → May 2021 | HIV infectious disease | Steven Deeks | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2022-05-27 | Inovio Pharmaceuticals | Results INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022 inovio.com ↗
Overall, INO-5401 + INO-9012 is demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. |
| 2021-06-03 | Geneos Therapeutics | Results Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program geneostx.com ↗
The treatment was generally safe and well tolerated with no treatment related serious adverse events noted on the trial. |
| 2020-11-20 | Inovio Pharmaceuticals | Results INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting inovio.com ↗
The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed GBM. |
| 2020-05-26 | Inovio Pharmaceuticals | Results INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer" inovio.com ↗ |
| 2020-05-14 | Inovio Pharmaceuticals | Results INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment inovio.com ↗
The Phase 1/2 clinical trial demonstrated that 84.4% percent (27 of 32) of patients with MGMT promoter unmethylated tumors, and 85% (17 of 20) of patients with MGMT promoter methylated tumors were alive at 12 months. |
| 2019-11-05 | Inovio Pharmaceuticals | Results Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) inovio.com ↗
80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months |
| 2019-01-24 | Inovio Pharmaceuticals | Results Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. |
| 2018-10-25 | Inovio Pharmaceuticals | Results Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX ® -GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the duration of the Phase 1 clinical study. |
| 2018-10-22 | Inovio Pharmaceuticals | Results Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150 inovio.com ↗
The study demonstrated a slowing of PSA doubling time, a measure of disease progression, in a majority of patients on the study. |
| 2018-10-02 | Inovio Pharmaceuticals | Results Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today a paper published in a major cancer journal detailed results of a patient with head and neck cancer treated with MEDI0457 achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor. |
| 2018-05-15 | Inovio Pharmaceuticals | Results Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial inovio.com ↗
More comprehensive immune analyses demonstrated that PENNVAX-GP (plus IL-12) generated HIV-specific CD4+ T cell and binding antibody response rates close to 100% when delivered with either CELLECTRA ® intramuscular or intradermal devices. |
| 2017-11-10 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference inovio.com ↗
Interim results presented at the conference show positive safety and tolerability data as well as the generation of hTERT-specific IFN-γ secreting T cells, suggestive of an ability to break immune tolerance. |
| 2017-05-24 | Inovio Pharmaceuticals | Results Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study inovio.com ↗
Notably, amongst the participants receiving PENNVAX-GP vaccine and IL-12 with intradermal immunization, 27 of 28 (96%) participants demonstrated a cellular response and 27 of 28 (96%) demonstrated an HIV env specific antibody response. |
| 2016-11-14 | Inovio Pharmaceuticals | Results Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer inovio.com ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured both in tumor tissue and in peripheral blood from subjects with head and neck cancer associated with human papillomavirus (HPV). |
All press releases naming this drug 14 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rocakinogene Sifuplasmid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02772003 ↗ |
| Known as | INO9012 | “2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P” NCT02514213 ↗13“INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:” NCT02501278 ↗ “1 mg of INO-9012 (DNA plasmid encoding human interleukin 12)” NCT02163057 ↗ “The INO-9012 vials will be supplied by Geneos Therapeutics” NCT04015700 ↗ |
| Known as | Rocakinogen sifuplasmida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594560 ↗ |
| Known as | Rocakinogene sifuplasmide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594560 ↗ |
| Modality | Vaccine | “INO-3106 alone or in combination with INO-9012 DNA vaccines” NCT02241369 ↗ |
| Route | Other | “delivered by Electroporation” NCT02241369 ↗ |